Cefditoren

Dosing

CAPAECBPharyngitis, tonsillitisUncomplicated SSTI400 mg PO q12h x14d400 mg PO q12h x10d200 mg PO q12h x10d200 mg PO q12h x10d

CAPAECBPharyngitis, tonsillitisUncomplicated SSTISafety and efficacy in pediatric patients <12y of age have not been established400 mg PO q12h x14d400 mg PO q12h x10d200 mg PO q12h x10d200 mg PO q12h x10d

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dose adjustmentNo data

CrCl >50CrCl 30-49CrCl 10-30CrCl <10HDCRRTNo dose adjustment200 mg PO q12h200 mg PO q24hNo data200 mg q24h (give after hemodialysis on dialysis days)No data

General Information

  • Acute bacterial exacerbation of chronic bronchitis

  • Community-acquired pneumonia

  • Infection of skin and/or subcutaneous tissue

  • Pharyngitis

  • Tonsillitis

Monitor culture/sensitivity when appropriate, white count with differential, and temperature.

Perform liver and renal function tests.

Monitor signs of toxicity (e.g. diarrhea, nausea, rash, vaginal discharge).

Common

  • Diarrhea

  • Nausea

  • Candida vaginitis

Serious

  • Erythema multiforme

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis

  • Hypersensitivity reaction

  • Acute renal failure

  • Interstitial pneumonia

  • Pulmonary eosinophilia

  • Probenecid: result in increased cefditoren pivoxil serum concentrations and bioavailability

  • Famotidine: result in decreased cefditoren serum concentrations

  • Cefditoren and antacids: result in decreased cefditoren effectiveness

  • Cholera vaccine, live

  • Oral contraceptives

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 1.6 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Therapeutic

Precautions:

  • Use caution in patients who have had previous hypersensitivity reactions to penicillins.

  • Not recommended if long-term therapy is indicated due to risk of developing carnitine deficiency; increased risk in patients with renal impairment or decreased muscle mass.

  • Prothrombin activity decreases may be associated with cephalosporin use, especially in patients with renal or hepatic impairment, poor nutritional state, prolonged course of antimicrobial therapy, or previously stabilized on anticoagulants; monitoring recommended.

  • If pseudomembranous colitis is diagnosed, discontinue therapy and treat with appropriate measures.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.